Six The phosphodiesterase-5 inhibitor sildenafil is licensed for PAH in FC I–IV from the United states and FC II–III in Europe. Endothelin receptor antagonists (ERAs) like bosentan, sitaxentan and ambrisentan are oral therapies accredited for use in PAH. As no oral agent has demonstrated superiority there continues to be debate https://riverjuppq.blogrelation.com/31918305/5-simple-statements-about-bosentan-explained